NEPHwork National AKI Audit

An audit of care quality in the identification and management of AKI stages 2 and 3 in acute NHS trusts in England and Wales in 2019





NEPHwork National AKI Audit

An audit of care quality in the identification and management of AKI stages 2 and 3 in acute NHS trusts in England and Wales in 2019

Suggested citation

NEPHwork National AKI Audit (2021) – an audit of care quality in the identification and management of AKI stages 2 and 3 in acute NHS trusts in England and Wales in 2019.

Publications based on data presented in this report must include the citation detailed above and the following disclaimer:

The data reported here have been supplied by the NEPHwork Consortium, funded by the UK Kidney Association (UKKA) and Kidney Research UK and supported by the UKKA UK Renal Registry and UKKA Renal SpR club. The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the UKKA or Kidney Research UK.

Contact information

For more information about this report or NEPHwork, please contact us:



nephwork@renalregistry.nhs.uk



@UKKidney



www.ukkidney.org

FOREWORD

Dr Graham Lipkin UKKA Past-President GIRFT Joint Clinical Lead for Renal Medicine



I strongly commend this important national acute kidney injury (AKI) audit. The NEPHwork structure crucially explored care processes and outcomes of almost 1,000 adult patients with the most severe stages of AKI (AKI stage 2 and 3) admitted across a sample of hospital trusts in England and Wales in 2019. Disturbingly, the audit demonstrates little improvement in the care and outcomes of patients with AKI over the past decade.

Acute kidney injury is a sudden, potentially reversible, loss of kidney function. Affecting up to one in five emergency hospital admissions, and 7.6% of admissions overall, it is associated with a marked increase in short term morbidity, a mortality of 18-33% by 30 days, substantial healthcare utilisation and costs (estimated between £400-600m/annum) and an increased subsequent risk of chronic kidney disease^{i ii}. For patients admitted in England in 2017, 32% of AKI developed in hospital, while 68% arose in the community or soon after admissionⁱⁱⁱ.

In 2009, the National Confidential Enquiry into Patient Outcome and Death (NCEPOD) report Acute Kidney Injury: Adding Insult to Injury, raised the profile of AKI and provided the impetus for national efforts to improve care^{iv}. Clinical experts reviewing cases of AKI in hospital where the patient died concluded that AKI could have been prevented in 15% of cases and that only 50% of patients received a standard of care that was considered 'good'.

I congratulate the NEPHwork initiative, a ground-breaking audit process, engaging renal trainees in national kidney data collection. It is enabled by the UK Kidney Association (UKKA), UK Renal Registry (UKRR) and Kidney Research UK (KRUK). The audit judged the care of patients against robust nationally accepted UK Kidney Association AKI Clinical Practice Guidelines 2019^v, identifying patients using the UKRR AKI master patient index with data coming directly from all English laboratories.

Ten years since the last National enquiry into care quality and outcomes of patients admitted to hospital with AKI, significant variation remains between trusts in the achievement of AKI care-quality measures with significant variations in assessment of AKI between different specialties. In-hospital mortality was 31% for all AKI episodes included. 30-40% of those discharged with AKI were readmitted within 90 days. The UKRR AKI dashboard describes case-mix adjusted benchmarking of patient mortality. It is almost certainly a measurable and reliable discriminator of the quality of acute care quality across all trusts and between medical and surgical specialities.

This report should act as a clarion call to healthcare commissioners and clinicians to focus attention on improving care quality and patient outcomes. Recent highquality evidence indicates that the introduction of a combination of AKI e-alerts, care bundles and education can lead to improved detection, reduced length of stay and enhanced quality of care, albeit without delivering any reductions to mortality^{vi}. The recommendations of NICE and UKKA AKI national guidelines together with the recent National Renal Getting it Right First Time (GIRFT) national report provide an important road map to deliver the care to which we all aspire^{vii}.

ⁱ Lameire, N.H., Bagga, A., Cruz, D. et al. (2013) Acute kidney injury: an increasing global concern. Lancet, 382(9887): 170–179. https://pubmed.ncbi.nlm.nih.gov/23727171/

^a Selby, N.M., Fluck, R.J., Kolhe, N.V. et al. (2016) International Criteria for Acute Kidney Injury: Advantages and Remaining Challenges. PLoS Med., 13(9): 1002122. https://journals.plos.org/ plosmedicine/article?id=10.1371/journal.pmed.1002122

iii https://www.ncepod.org.uk/2009akitoolkit.html

^{iv} https://www.ncepod.org.uk/2009akitoolkit.html

* https://ukkidney.org/sites/renal.org/files/FINAL-AKI-Guideline.pdf

^{vi} Selby, N.M., Casula, A., Lamming, L. et al. (2019) An Organizational-Level Program of Intervention for AKI: A Pragmatic Stepped Wedge Cluster Randomized Trial. J.Am.Soc.Nephrol., 30(3): 505–515 https://jasn.asnjournals.org/content/30/3/505

vii https://ukkidney.org/sites/renal.org/files/Renal%20Medicine%20Sept21k.pdf

FOREWORD

Dr Hannah Beckwith UKKA Renal SpR Club Committee Chair



This audit represents Nephrology's first trainee-led national multicentre collaborative project. It is the culmination of outstanding commitment, enthusiasm and teamwork from registrars across England and Wales, and is particularly impressive given the challenges and competing priorities over the last 18 months.

This outstanding piece of work is no doubt the first of many high quality academic outputs to come from the NEPHwork community- huge congratulations and thank you to all who have been involved.

Executive Summary	6
Introduction	8
Acute Kidney Injury: definition and burden	8
AKI algorithm and UK Renal Registry Master Patient Index	8
NEPHwork National AKI Audit	9
Objectives of the report	9
Methods	10
NEPhwork workforce	10
Audit process and identification of hospitalised AKI episodes	10
Organizational survey	11
Statistical methods	11
Data return and clinicodemographic features of AKI episodes	12
Attainment of care quality indicators	15
Outcomes of AKI episodes	20
Principal Conclusions	22
References	23
Acknowledgements	23
Appendices	26

EXECUTIVE SUMMARY

INTRODUCTION

Acute kidney injury (AKI) is a sudden deterioration of kidney function that is accompanied by high morbidity and mortality.

From the 2009 National Confidential Enquiry into Patients Outcomes and Deaths (NCEPOD) report (Acute Kidney Injury: Adding Insult to Injury) approximately 1,000 episodes of AKI care in people who died in England with an ICD-10 code for AKI (N17) contained in Hospital Episode Statistics (HES) were reviewed. Of these episodes, in only 50% of cases was AKI care considered good by consultants. The audit found poor assessment of risk factors for AKI and an unacceptable delay in recognition of AKI post-admission, which corresponded to 43% of cases reviewed. In one-fifth of AKI episodes reviewed, AKI was considered predictable and therefore avoidable, and complications of AKI were missed in 13%, avoidable in 17%, and poorly managed in 22% of cases.

Since 2014, NHS England mandated all testing laboratories in England to incorporate AKI alert test scores (AKI alerts) into their laboratory testing systems with the aim to improve both early detection and outcomes of AKI. In addition, with the aim of facilitating nationwide related analyses of AKI care, these AKI alerts have since been regularly sent to the UK Renal Registry (UKRR) along with demographic data. This allowed the publication in 2019 of the first UKRR AKI report which was based on the analysis of the alerts sent to the UKRR in 2018.

The establishment of the NEPHwork consortium, with support from the UK Kidney Association (UKKA), UKRR and Kidney Research UK, has allowed trainees in nephrology to be brought together to conduct audit and/or research projects on a national scale. The first project chosen was the NEPHwork AKI National Audit which, 10 years after the publication of the NCEPOD report, has aimed to describe the hospital standard of care for AKI in its most severe stages, AKI stage 2 and 3, and to explore the achievement of current guidelines in the recognition and management of AKI.

A workforce of 57 SpRs from the UKKA SpR club reviewed almost 1,000 care episodes across 24 NHS acute trusts in England and Wales. Between 1st December 2020 and 28th February 2021, electronic and paper care-records for patients with AKI episodes admitted to hospital between December 2018 and February 2019, were reviewed by renal SpRs within each hospital trust against an agreed proforma based on the UKKA AKI guidelines published in 2019.

KEY FINDINGS

- 989 AKI care episodes were included in the analyses, of these 50.3% were AKI stage 2 and 49.7% AKI stage 3.
- Approximately 73% of all AKI episodes included occurred in patients aged≥ 65 years, 54% in males, 90% in people of White ethnicity.
- For both stage 2 and stage 3 AKI, there were no differences between groups of different socioeconomic deprivation status.
- Ten years since the last National enquiry into care quality and outcomes of patients admitted to hospital with AKI, significant variation remains between organizations in the achievement of care-quality measures, in particular for those related to clinical assessment of AKI.
- Variations in clinical assessment of AKI were also found between different specialties.
- In almost 20% of cases the discharge summary did not mention AKI.
- 24 (2.4%) AKI episodes required long-term dialysis.
- 90-day re-admission rate amongst AKI survivors was high and between 30-40%.
- In-hospital mortality was high and about 31 % for all AKI episodes included.
- 30-day mortality was also high at 33%, reaching 35.4% in AKI stage 3.

CONCLUSIONS

This is the first audit report that, using AKI alerts collected by the UKRR directly from laboratories, describes the attainment of guidelines in the identification and management of hospitalised AKI episodes. This audit report is therefore the first one to explore how in-hospital standards of care of AKI have improved 10 years after the NCEPOD report and 5 years after the introduction of the AKI alerts in the NHS, providing essential data for both service planning and QI projects development in this area.

INTRODUCTION

ACUTE KIDNEY INJURY – DEFINITION AND BURDEN

Acute kidney injury (AKI) is a sudden decline in kidney function that lasts from a few hours to a few days. Recognised examples of risk factors include advanced age and pre-existing conditions, such as chronic kidney disease (CKD)¹.

AKI is a significant cause of mortality and morbidity and carries significant healthcare costs².

From the 2009 National Confidential Enquiry into Patients Outcomes and Deaths (NCEPOD) report (Acute Kidney Injury: Adding Insult to Injury), in which approximately 1,000 AKI care episodes were reviewed in people who had died in England with an ICD-10 code for AKI (N17) held in Hospital Episode Statistics (HES)³, only 50% of AKI care was considered good by the advisors. There was poor assessment of risk factors for AKI and an unacceptable delay in recognising postadmission AKI in 43% of patients. A fifth of post-admission AKI was both predictable and avoidable, and complications of AKI were missed in 13%, avoidable in 17% and managed badly in 22% of cases.

Following the publication of the NCEPOD report, the need therefore arose to improve the ability to detect and manage AKI in the health service. This was the spark that led to the development of quality improvement projects, first and foremost, the "Think Kidneys" programme that was instrumental in the development of the NHS England funded AKI warning test score or alert system and enabled the introduction of the AKI alert system into the NHS laboratories.

AKI ALGORITHM AND UK RENAL REGISTRY MASTER PATIENT INDEX

As of March 2015, NHS England has implemented a standardised biochemical classification of AKI by installing an algorithm in their laboratory information management system⁴.

The algorithm compares a person's serum creatinine with their historical blood tests (if any) to determine if the person may have AKI.

The AKI algorithm has five possible outcomes, three of which are AKI warning test scores or alerts (from the least severe AKI stage 1 to the most severe AKI stage 3). These results are in agreement with the Kidney Disease: Improving Global Outcomes (KDIGO) AKI staging system⁵:

- 1. Null (no evidence of AKI).
- 2. Stage 1 AKI.
- 3. Stage 2 AKI.
- 4. Stage 3 AKI.

5. Not applicable (insufficient creatinine values but marked as abnormal if outside the reference range).

Laboratories are required to send such alerts to the UKRR along with basic demographic information on all persons detected by the algorithm. The UKRR collates these AKI alerts (stages 1, 2 and 3) into a single Master Patient Index (MPI), which each adult or child in England who has had an AKI alert.

NEPHWORK NATIONAL AKI AUDIT

The aim of the renal specialty (SpR) trainee driven NEPHwork was to develop, coordinate and deliver audit and research projects that answer specific and simple questions on a large scale by coordinating the audit and research activity of a large number of renal trainees nationally. The NEPHwork is supported by a collaboration between the UKKA and Kidney Research UK. The first NEPHwork project was an audit of the care provided to people with an acute kidney injury (AKI): the NEPHwork National AKI Audit.

10 years after the results of the NCEPOD audit and following the improvement projects introduced, NEPHwork therefore set out to audit whether and how identification and management of AKI had improved.

OBJECTIVES OF THE REPORT

The NEPHwork National AKI Audit aims are to explore care process and outcomes of adult patients with the most severe stages of AKI (AKI stage 2 and 3) admitted across a sample of hospital trusts in England and Wales in 2019. The audit proforma (Appendix) was developed by the NEPHwork steering committee against <u>the</u> <u>UKKA's AKI clinical practice guideline 2019</u>. The audit explored the attainment of prompt recognition of AKI as outlined in the guidelines and its subsequent clinical management in accordance with the guidelines.

METHODS

NEPHWORK WORKFORCE

Twenty-four NHS acute trusts took part in the NEPHwork National AKI Audit with a target of 1,000 care episodes reviewed by a workforce of 57 SpRs from the UKKA SpR club. Between 1st December 2020 and 28th February 2021, electronic and paper care-records for patients with AKI episodes admitted to hospital between December 2018 and February 2019, were reviewed by renal SpRs within each hospital trust against the agreed proforma. The full list of the NEPHwork workforce is available at the end of this report.

AUDIT PROCESS AND IDENTIFICATION OF HOSPITALISED AKI EPISODES

AKI care episodes in England were identified using the linkage between the UKRR AKI-MPI of AKI warning test scores and Hospital Episodes Statistics (HES). A prepopulated pro-forma for each patient identifier and AKI date was made available electronically by the UKRR through a specially designed, secure, electronic portal that was accessible to SpRs completing the audit locally. SpRs reviewed patient notes and records for the selected episodes and then returned the data using the electronic pro-forma through the secure UKRR data portal.

An AKI episode was defined by one or more e-alerts separated by no more than 30 days (figure 1), i.e. if more than one alert was present, all alerts following the first were considered part of the episode unless a 30-day alert-free period had passed. AKI episodes identified from the UKRR-MPI were linked to HES data to identify hospitalised patients with AKI.




Figure 1 AKI episode definition

For this audit, adult patients that had an AKI-episode which started any time between one week before and two weeks after hospital admission were included, resulting in both community-acquired hospitalised (CAH) AKI subsequently hospitalised and hospital-acquired (AH) AKI cases being selected. A further inclusioncriterion was the presence of an AKI-alert at stage 2 or 3 at any point during the first 2 weeks in hospital. Day-cases and maternity admissions were excluded.

A point-by-point guide was produced and sent to the Wales representative of the NEPHwork Steering Committee for the AKI audit so that the same selection criteria for identifying AKI episodes could be applied. In Wales the episodes were selected from the hospital data on hospital AKI alerts available in Wales for the same period. The analyses of this audit were carried out for the whole cohort and at centre level. Centre-level analyses were sent at the end of August 2021 to each centre participating in the audit so that each centre could compare its performance in meeting the AKI standards of care against the average of all participating centres in the NEPHwork audit.

DATA SOURCES

Data available for this audit came from various sources. The AKI-MPI provided demographic information on age and gender. Patients' residence postcodes were available via the AKI-MPI dataset for English patients, while for Welsh patients they were obtained through tracing from the NHS Batch Demographics Service. Postcodes were then used to assign patients the Index of Multiple Deprivation (IMD)², a measure of relative deprivation for small areas, categorised into quintiles for analysis (from 1=least deprived to 5=most deprived group).

Ethnicity was obtained using the HES linkage for English patients, while it was asked as an extra variable during the audit for Welsh patients. Hospital admissions were classed as elective or emergency admissions based on the admission-method available from HES-linkage, and divided into admission with hospital-acquired AKI (HA-admissions) or community-acquired AKI (CA-admissions) based on time between first AKI-alert and hospital admission (HA- if AKI commencing from day 3 of a hospital admission, CA- if AKI beginning outside of hospital, or within the first 2 days of an admission). The NHS Batch Demographics Service was used to trace dates of death for all patients. The pro-forma is shown in its entirety in the appendix.

ORGANIZATIONAL SURVEY

Registrars were asked to complete a 13-question survey about the organisation of their renal service. Data about the survey was sent by email and collected through a spreadsheet which was returned by the end of the audit period.

STATISTICAL METHODS

Demographic characteristics and audit metrics are presented as percentages for categorical variables and as median and interquartile range (IQR) for continuous variables, for the full cohort and separately by peak AKI-stage, with no test for differences between groups performed.

Variation between hospitals in the attainment of quality indicators is shown with funnel plots, with hospital level of attainment adjusted for age and sex using logistic analysis.

Outcomes such as in-hospital or 30day mortality, re-admission or recovery of renal function are summarised for the full cohort and by peak AKI-stage. Variation in in-hospital mortality rate between hospital, adjusted by age and sex using logistic analysis, is presented as a funnel plot.

All analyses were performed using SAS version 9.4.

DATA RETURN AND CLINICODEMOGRAPHIC FEATURES OF AKI EPISODES


The NEPHwork AKI national audit was attended by 57 registrars from 24 NHS acute Trusts of which 22 were in England and 2 in Wales. The audit covered 8 of the 9 English regions with the exception of the Northwest where, unfortunately, the concomitant COVID-19 pandemic made it impossible for centres in this area to participate.



Figure 1.1 map of NEPHwork AKI national audit participants in England and Wales

Against the target of 1000 records 1187 records were returned as complete and of these 989 were included in the study cohort.





Approximately 73% of all AKI episodes occurred in patients aged \geq 65 years, 54% in males, 90% in people of White ethnicity. For both stage 2 and stage 3 AKI, there were no differences between groups of different socioeconomic deprivation status. All sociodemographic and clinical features of AKI episodes are summarised in table 1.1.

Variables	Peal	Peak-2 AKI		k-3 AKI	AL	L AKI	
Total N (%)	498	50.3	491	49.6	989		
Age group N (%)							
18-29	10	2	7	1.4	17	1.7	
30- 49	31	6.2	46	9.4	77	7.8	
50- 64	72	14.5	96	19.6	168	16.9	
65 - 74	109	21.9	99	20.2	208	21	
75 - 84	157	31.5	141	28.7	298	30.1	
≥85	119	23.9	102	20.8	221	22.3	
Sex N (%)							
Female	245	49.2	209	42.6	454	45.9	
Male	253	50.8	282	57.4	535	54.1	

Table 1.1 Sociodemographic and clinical features of AKI episodes overall and by peak stage AKI

IMD quintile N (%) - missing N=2						
deprivation score-1 (least-deprived)	101	20.3	85	17.3	186	18.8
deprivation score-2	115	23.1	102	20.8	217	22
deprivation score-3	98	19.7	104	21.2	202	20.5
deprivation score-4	99	19.9	89	18.2	188	19.1
deprivation score-5 (most deprived)	84	16.9	110	22.4	194	19.7
Ethnicity N (%) - missing N= 72 (33 Eng + all W	ales)					
Asian	18	3.8	14	3.1	32	3.5
Black	16	3.4	20	4.5	36	3.9
Other/Mixed	11	2.4	11	2.4	22	2.4
White	423	90.4	404	90	827	90.2
Cause of AKI N (%)						
Hypovolemia	151	30.3	115	23.4	266	26.9
Circulatory failure	51	10.2	59	12	110	11.1
Sepsis	166	33.3	149	30.3	315	31.8
Rhabdomyolysis	3	0.6	2	0.4	5	0.5
Nephrotoxicity	16	3.2	24	4.9	40	4
Obstruction	32	6.4	68	13.8	100	10.1
Multifactorial	17	3.4	34	6.9	51	5.1
No specific cause	56	11.2	36	7.3	92	9.3
Not completed	6	1.2	4	0.8	10	1
Type-AKI N (%) - from AKI-MPI+HES England o	nly (n=95	0)		•		•
САН	334	69.2	351	75.2	685	72.1
НА	149	30.8	116	24.8	265	27.9
Type-admission N (%)- from HES England-only	, (n=950)		•	•	•	•
Elective	40	8.3	28	6	68	7.2
Emergency	443	91.7	439	94	882	92.8
Admission specialty N (%)		- T-	- ^			-
Medicine	350	70.3	364	74.1	714	72.1
Surgery	109	21.9	86	17.5	195	19.7
ITU	24	4.8	30	6.1	54	5.4
Discharged from ED	3	0.6	1	0.2	4	0.4
Other	11	2.2	10	2	21	2.1
Not completed	1	0.2	0	0	1	0.1
Creatinine re-checked within 30 days N (%), if	221	67	224	75.2	445	70.9
alive 30days after discharge, N=628 (330 AKI						
stage 2 - 298 AKI stage 3)						
Life-threatening complications N (%) missing	N = 17					
Hyperkalaemia	59	11.9	130	26.5	189	19.2
Uraemia	61	12.2	114	23.3	175	17.7
Pulmonary oedema	51	10.3	52	10.6	103	10.5
Acidosis	134	27.2	204	41.8	338	34.5
Median Length of Stay (IQR)	10	(5-19)	11	(5-20)	10	(5-20)

All participating centres completed the organizational survey conducted in parallel with the collection of audit data, results are shown in table 1.2.

Table 1.2 Results of organizational survey.	1.
---	----

QUESTIONS		
How many days per week you have a consultant nephrologist on site?	N	%
2 days	1	4
5 days	2	8
7 days	21	88
	N-Yes	% Yes
Is emergency RRT service available 24 hours a day 7 days a week?	24	100
Are there locally derived guidelines (for example, via abnormality flags on pathology	23	96
results) to encourage timely referral into the in-hospital renal service?		
Is there a communication guidance to local hospitals to ensure prompt access to	15	62
renal specialists to discuss cases; this will include written criteria to ensure safe transfer?		
Is there a communication guidance with local primary care to ensure prompt access to renal specialists to discuss cases?	21	88
Are available trained nurses able to deliver intermittent haemodialysis 24 hours	20	83
a day 7 days a week, separate from the delivery of treatment to patients with		
established renal failure?		
Is Renal unit staffed so that there is access to trained nurses to deliver plasma	20	83
exchange seven days a week within 24 hours of a patient being identified as		
requiring plasma exchange treatment.?		
Is a dialysis access available in appropriate settings 24 hours a day? Appropriate	20	83
settings include operating theatres, radiology departments and clean areas on renal wards		
Is access to the following medical specialties available 24 hours a day: urology,	24	100
critical care, general and vascular surgery, cardiology, haematology and obstetrics?		
Is access to renal ultrasound available within 24 hours of presentation?	21	88
Is access to process specialised tests, such as immunology and specialty	22	92
biochemistry, available 5 days a week?		
Is access to routine biochemistry, haematology and blood transfusion services	24	100
available 24 hours a day?		
Is access to interventional radiology and clinical microbiology available 7 days a week?	19	79

ATTAINMENT OF CARE QUALITY INDICATORS

Timely clinical assessments after admission varied by type of assessment, ranging from 37% of episodes for the request of an ultrasound scan within 24 hours of admission (6 hours if pyelonephritis was suspected) to 87% for fluid balance assessment. Overall, the standard AKI interventions were completed in more than 80% of all episodes. Attainment of quality indicators for both assessment and clinical management of AKI and its follow-up are shown in table 2.1.

Variables	Peak-2 AKI		Peak-3 A	KI	ALL AKI	
Total N (%)	498	50.3	491	49.6	989	
Clinical Assessment: timely review N (%)						
Consultant review within 6 hours	283	58	288	59.8	571	58.9
Medication review (dose adjustments and	392	79.5	400	82.1	792	80.8
discontinuation within 6 hours)						
Fluid balance assessment (Fluid balance assessment	425	86.2	425	87.5	850	86.8
within 6 hours)						
Urinalysis test recorded	173	35.5	233	48.3	406	41.9
USS renal tract [within 24hrs (<6hrs if pyelo) or any	139	27.9	228	46.5	367	37.2
other imaging to exclude obstruction]						
Blood/gas acid-base recorded	328	66.3	372	76.2	700	71.2
Clinical management: timely Interventions - treatment			1		1	
completed when indicated N (%)						
Antibiotics (Within 1 hour) (indicated, with data,	274	90.7	271	87.4	545	89.1
N=612, 302 AKI stage 2 - 310 AKI stage 3)						
IV fluids (indicated, with data, N=798, 400 AKI stage 2 -	384	96	391	98.2	775	97.1
398 AKI stage 3)						
Diuretics (indicated, with data, N=93, 47 AKI stage 2,	47	100	45	97.8	92	98.9
46 AKI stage 3)						
Bladder catheterization (indicated, with data, N=525,	210	92.9	281	94	491	93.5
226 AKI stage 2 - 299 AKI stage 3)						
Nephrostomy/stent (indicated, with data, N=52, 14	13	92.9	33	86.8	46	88.5
AKI stage 2 - 38 AKI stage 3)						
Follow-up: Discharge letter including AKI diagnosis - N						
(%)						
AKI mentioned on discharge letter (alive at discharge,	250	71.7	285	87.7	541	79.3
N= 682, 357 AKI stage 2 - 325 AKI stage 3)						
GP Instructions re medicine and blood tests on	177	64.6	187	67	364	65.8
discharge letter when applicable (with data N = 553,						
274 AKI stage 2 - 279 AKI stage 3)						
Follow-up of unresolved renal function mentioned on	98	58	131	65.2	229	61.9
discharge letter (applicable, with data, N= 370, 169 AKI						
stage 2 - 201 AKI stage 3)						
Nephrology Involvement N (%)						
One off advice when applicable (with data N=531, 225	50	22.2	110	35.9	160	30.1
AKI stage 2 - 306 AKI stage 3)						
Ongoing review when applicable (with data N = 488,	34	17.5	141	48.0	175	35.9
194 AKI stage 2 - 294 AKI stage 3)						
Take-over including RRT when applicable (with data N	4	2.1	54	19.9	58	12.7
= 458, 187 AKI stage 2 - 271 AKI stage 3)						
Transferred to secondary care when applicable (with	6	3.0	46	18.1	52	11.4
data = 457, 203 AKI stage 2 - 254 AKI stage 3)						
ICU involvement N (%)						

Take over from Nephrology when applicable (with	13	6.4	29	10.8	42	8.9
data N= 457, 203 AKI stage 2 - 254 AKI stage 3)						
Advice from Intensivist when applicable	97	19.5	133	27.1	230	23.3
Take-over supportive management when applicable		13.1	83	16.9	148	15.0
Take-over RRT when applicable	21	4.2	59	12.0	80	8.1
ICU involvement NOT applicable	212	43.3	211	43.2	423	43.2


A stratified analysis shows that completion of assessments varied based on the admitting specialty. While overall compliance with requesting diagnostic imaging was low, it improved if the admitting specialty was Surgery compared to Medicine (48% vs 35% of all episodes). In contrast, compliance with medication review was slightly better when the admitting specialty was Medicine compared to Surgery (82% vs 71% of all episodes) (table 2.2).

Table 2.2 Attainment of quality indicators by speciality

Variables	Medicine		Medicine Surger				/ED/ ners
otal N (%)			195		79		
Clinical Assessment: timely review N (%)							
Consultant review within 6 hours	419	59.7	88	46.1	63	82.9	
Medication review (dose adjustments and	585	82.7	137	71.0	69	87.3	
discontinuation within 6 hours)							
Fluid balance assessment (Fluid balance assessment	621	87.8	155	80.3	73	93.6	
within 6 hours)							
Urinalysis test recorded	315	44.9	61	32.1	30	39.0	
USS renal tract [within 24hrs (<6hrs if pyelo) or any other	251	35.2	95	48.7	21	26.6	
imaging to exclude obstruction]							
Blood/gas acid-base recorded	511	72.1	121	62.4	67	84.8	
Clinical management: timely Interventions - treatment							
completed when indicated N (%)							
Antibiotics (Within 1 hour) (indicated, with data,	403	90.0	96	83.5	45	93.8	
med=448, surg=115, other=48)							
IV fluids (indicated, with data, med=572, surg=165,	557	97.4	158	95.8	59	98.3	
other=60)							
Diuretics (indicated, with data, med=81, surg=6, other=6)	80	98.8	6	100	6	100	
Bladder catheterization (indicated, with data,med=345,	318	92.2	116	94.3	56	100	
surg=123, other=100)							
Nephrostomy/stent (indicated, with data, med=28,	24	85.7	22	91.7	na	na	
surg=24, other=none)							


Median length of stay in hospital for all AKI episodes included in the audit was highly variable across hospitals participating in the project.

Figure 2.1 Caterpillar plot of hospital length of stay in all stages of AKI (includes patients that died in hospital)



The inter-hospital variation in the attainment of the quality indicators for both timely AKI assessment and clinical management depended on the type of quality indicator considered and is shown adjusted by sex and age.

Figure 2.2 Funnel plots showing inter-hospital variations in attainment of quality indicators for AKI assessment, adjusted for age and sex: a) consultant review within 6 hours, b) medication review (dose adjustments and discontinuation) within 6 hours, c) fluid balance assessment within 6 hours, d) urinalysis test recorded, e) blood/gas acid-base recorded, f) timely review of USS renal tract/other imaging to exclude obstruction







Figure 2.3 Funnel plots showing inter-hospital variations in attainment of quality indicators for AKI interventions when clinically indicated, adjusted for age and sex: a) antibiotics within 1 hour, b) IV fluids, c) bladder catheterization, d) discharge letter including AKI diagnosis



OUTCOMES OF AKI EPISODES

Outcomes of AKI episodes included in the study are summarised in Table 3.1 overall and by peak stage AKI.

Variables	iables Peak-2 AKI		Peak-3 AKI		ALL AKI	
Total N (%)	498	50.3	491	49.6	989	
Re-admission within 90- days N (%), if alive after		32.6	115	40.6	214	36.5
90days after discharge, N=587 (304 AKI stage 2 -						
283 AKI stage 3)						
Renal function back to baseline N (%)	286	57.4	209	42.6	495	50.1
Entered maintenance dialysis N (%)	4	0.8	20	4.1	24	2.4
In-hospital mortality N (%)	141	28.3	166	33.8	307	31
30-day mortality N (%)	153	30.7	174	35.4	327	33.1

Table 3.1 Outcomes of AKI episodes overall and by AKI peak stage

Inter-hospital variations related to in-hospital mortality, 30-day mortality and readmission within 90 days from discharge are shown as sex-age adjusted.

Figure 3.1 Funnel plot showing inter-hospital variations in in-hospital mortality, adjusted for sex and age, for all AKI episodes




Figure 3.2 Funnel plot showing inter-hospital variations in 30-day mortality, adjusted for sex and age, for all AKI episodes





Figure 3.3 Funnel plot showing inter-hospital variations in re-admission within 90 days of discharge, adjusted for sex and age, for all AKI episodes



PRINCIPAL CONCLUSIONS

- Cases identified in the NEPHwork AKI audit using the Nationally mandated AKI warning test score were significantly more likely to have clinical AKI (989 out of 1187 episodes) than those identified through clinical coding in the previous NCEPOD audit supporting the research findings that the warning algorithm is specific⁶. The case selection method means that no comment is possible on any cases of clinical AKI not detected.
- Consistent with other analysis of patient with AKI stages 2 and 3⁸ in-hospital mortality is high (approximately 30%), with most but not all deaths occurring in hospital and very similar outcomes between the two AKI.
- Ten years since the last National enquiry³ into care quality and outcomes
 of patients admitted to hospital with AKI there remains significant variation
 between organisations in the achievement of care-quality measures. Many
 of these are well established NICE recommendations [NICE QS174 2018]. For
 a condition associated with a 30% mortality it is disappointing that only 60%
 achieved the QS174 standard of a consultant review in 6 hours.
- The NEPHwork AKI audit differed from the NCEPOD audit because it included survivors of hospital admissions including an episode of AKI whilst the NECPOD audit only reviewed the care of those who had died. The proportion of people who achieved each care standard cannot therefore be directly compared.
- Discharge from hospital is a key transition of care, and given a 90 day readmission rate amongst AKI survivors of between 30-40% it is disappointing that the discharge summary did not mention AKI in 20% of cases.
- Although only 24 (2.4%) people required long-term dialysis this represents a significant health burden for these people, and a significant increase in cost to long-term care.

REFERENCES

- 1. National Institute of Health and Clinical Excellence (2013). Acute kidney injury: prevention, detection and management. Available from: nice.org.uk/guidance/cg169.
- 2. Kerr M, Bedford M, Matthews B, O'Donoghue D (2014). The economic impact of acute kidney injury in England. Nephrol. Dial. Transplant. 29: 1362–1368.
- 3. NCEPOD (2009). Acute Kidney Injury: Adding Insult to Injury (2009). Available from: ncepod.org. uk/2009akitoolkit.html.
- 4. NHS England (2015) Acute kidney injury (AKI) algorithm. Available from: england.nhs.uk/ akiprogramme/aki-algorithm.
- 5. Kidney Disease: Improving Global Outcomes (KDIGO) (2012) KDIGO clinical practice guideline for acute kidney injury. Kidney Int. 2 (suppl. 1): 1–138.
- 6. Sawhney S et al. (2015). Maximising Acute Kidney Injury Alerts a cross-sectional comparison with the clinical diagnosis. PLOS ONE 10: e0131909. 11.
- 7. GOV.UK (2015). English indices of deprivation 2015. Available from: gov.uk/government/ statistics/ english-indices-of-deprivation-2015
- 8. Selby NM et al. (2019). An organizational-level program of intervention for AKI: a pragmatic stepped wedge cluster randomized trial. J. Am. Soc. Nephrol. 30: 505–515.

ACKNOWLEDGEMENTS

We thank the UKKA and KRUK for their support of the NEPHwork National AKI audit. We also thank the UKKA Renal SpR Club members who helped to recruit members of the NEPHwork Consortium National AKI Audit.

We acknowledge and thank all members of the NEPHwork Consortium National AKI Audit for their hard work in collecting data especially during the difficult time due to the COVID-19 pandemic.

We acknowledge the NEPHwork National AKI Audit Steering Committee who coordinated the project and made its realisation possible: Matthew Graham-Brown, Manuela Savino, Toby Humphrey, Rhodri Pyart, James Medcalf, Adnan Sharif, Mark Andrews, Suren Kanagasundaram and Elizabeth Wallin.

We thank the UKRR staff who facilitated the realisation of the National AKI audit project and the production of this report.

We acknowledge Jennifer Williams and Kirsty Crowe new NEPHwork Steering Committee members for their contribution to the dissemination of the results of the National AKI audit developed by the NEPHwork Consortium.

NEPHWORK CONSORTIUM NATIONAL AKI AUDIT

Dr Keegan Lee, St George's University Hospitals NHS Foundation Trust, Data collection Dr Dan Cooper, Cambridge University Hospitals NHS Foundation Trust, Data collection Dr Edward Carr, Cambridge University Hospitals NHS Foundation Trust, Data collection Dr Amar Marthi, East and North Hertfordshire NHS Foundation Trust, Data collection Dr Oscar Swift, East and North Hertfordshire NHS Foundation Trust, Data collection Dr Katherine Hull, University Hospitals of Leicester NHS Foundation Trust, Data collection Dr Ailish Nimmo, North Bristol NHS Foundation Trust, Data collection Dr Hui Liew, North Bristol NHS Foundation Trust, Supervision & coordination of data collection

Dr Behram Tariq, South Tees Hospitals NHS Foundation Trust, Data collection Dr Jenny Whitehead, South Tees Hospitals NHS Foundation Trust, Data collection Dr Naomi Edney, Royal Devon and Exeter Hospital NHS Foundation Trust, Data collection Dr Daniel Whitbread, Royal Devon and Exeter Hospital NHS Foundation Trust, Data collection

Dr Maha Mohamed, Newcastle Upon Tyne Hospital NHS Foundation Trust, Data collection Dr Sam Duffy, South Tyneside and Sunderland NHS Foundation Trust, Data collection Dr Gwenno Edwards, Cardiff & Vale University Health Board, Data collection Dr Rachael Czajka, Bradford Teaching Hospitals NHS Foundation Trust, Data collection Dr Syed Hasan Ahmad, East Suffolk North Essex NHS Foundation Trust, Data collection Dr Jennifer Joslin, King's College Hospital NHS Foundation Trust, Data collection Dr Esther Siaw Tsin Yong, Western Sussex University Hospitals NHS Foundation Trust, Data collection

Dr Saurabh Chaudry, Barts Health NHS Trust, Supervision & coordination of data collection Dr Daniel McGuinness, Barts Health NHS Trust, Supervision & coordination of data collection

Dr Sarah Defreitas, Barts Heath NHS Trust, Supervision & coordination of data collection Dr Heba Nosseir, Brighton & Sussex University Hospitals NHS Foundation Trust, Data collection

Dr Katherine Seal, Brighton & Sussex University Hospitals NHS Foundation, Data collection Dr Mo Amaran, Epsom and St Helier NHS Foundation Trust, Data collection

Dr Kavita Gulati, Imperial College Healthcare NHS Trust, Data collection

Dr Muhammad J Azam, University Hospitals of North Midlands NHS Trust, Data collection Dr Jennifer Williams, University Hospital Plymouth NHS Trust, Data collection

Dr Smith-Jackson, Newcastle Upon Tyne Hospital NHS Foundation Trust, Data collection

Dr Bo-song Yin, Royal Wolverhampton NHS Trust, Data collection

Dr Rishana Shuaib, Imperial College Healthcare NHS Trust, Data collection

Dr Mosammat Akter, Imperial College Healthcare NHS Trust, Data collection

Dr Ryoki Arimoto, Royal Berkshire Hospital NHS Trust, Data collection

Dr Rotimi Oluyombo, Norfolk and Norwich University Hospitals NHS Foundation Trust, Data collection

Dr Mark Davies, Betsi Cadwalader University Health Board, Data collection Dr Purvi Patel, Royal Berkshire Hospital NHS Foundation Trust, Data collection Tony Best-Trent, University Hospitals Plymouth NHS Trust, Data collection Dr Heidy Handra, Barts Health NHS Trust, Data collection Sarah Mackie, King's College Hospital NHS Foundation Trust, Data collection Kelly Wright, King's College Hospital NHS Foundation Trust, Data collection Dr Manzur Rahman, University Hospitals of North Midlands NHS Trust, Data collection Dr Hashem Cheema, Oxford University Hospitals NHS Foundation Trust, Data collection Dr Abbas Sardar, Oxford University Hospitals NHS Foundation Trust, Data collection Dr Lucy Harvard, Cambridge University Hospitals NHS Foundation Trust, Data collection Dr Matthew Brook, Oxford University Hospitals NHS Foundation Trust, Data collection Dr Emma Elphic, Shrewsbury and Telford Hospital NHS Trust, Data collection Dr Mawahib Ahmed, South Tees Hospitals NHS Foundation Trust, Data collection Dr Kanbar Ammar, University Hospitals of North Midlands NHS Trust, Data collection Dr Madi Harbe, East Suffolk North Essex NHS Foundation Trust, Data collection Dr Emma Corke, Royal Devon and Exeter Hospital NHS Foundation Trust, Data collection Dr Hannah Stacey, Cambridge University Hospitals NHS Foundation Trust, Data collection Dr Mosab Yousif, Barts Health NHS Trust, Data collection

Dr Dalal Mohamed, Norfolk and Norwich University Hospitals NHS Foundation Trust, Data collection

Dr Lae Thandar Soe, Norfolk and Norwich University Hospitals NHS Foundation Trust, Data collection

Dr Adenwalla Sherna, University Hospitals of Leicester NHS Foundation Trust, Data collection

Dr Lauren Soutter, Barts Health NHS Trust, Data collection

Dr Maria Davari, Barts Health NHS Trust, Data collection


Dr Sneha Abburu, Barts Health NHS Trust, Data collection

Dr James Wells, Barts Health NHS Trust, Data collection

Dr Claire Winterbottom, Oxford University Hospitals NHS Foundation Trust, Data collection Dr Matt Bottomley, Oxford University Hospitals NHS Foundation Trust, Supervision & coordination of data collection

- Dr Holly Morris, University Hospital Plymouth NHS Trust, Data collection
- Dr Anavami Sadiq, University Hospital Plymouth NHS Trust, Data collection
- Dr Sajeda Youssouf, Barts Health NHS Trust, Supervision & coordination of data collection

APPENDICES



Conceptual design: Members of the consensus group whose names and meeting report can be accessed on: http://www.acb.org.uk/docs/E-Alerts_for_AKI_meeting_statement Graphic design: Robert Desborough, Mike Bosomworth, Robert Hill

NEPHWORK DATA-ENTRY FORM

					Username Options
pdate Record					
•	lopment of AKI	Timely Completion of AKI Review	Timely Completion of AKI Inteve	ntions Life th	reatening complications
		ninely completion of Alt Neview	Timely completion of Akt inteve	intions the th	reacting complications
ephrology Involvement ITU Involvement	TTO				
IHS number*					
upplied NHS number					
irst name*	Last name*		Date of birth*		Hospital*
					
pplied first name	Supplied last name		Supplied date of birth		HES supplied hospital
entity confirmed*		Reviewer			
Not Completed	~		~		
nfirm patient record matches details in patient file		Name of who reviewed this patient			
dmission date*		Admission type*		Admission speci	ality#
		Not Completed	*	Not Complete	
mission date for patient should be within two weeks of au	nt			First destination pos	at ED
phwork Home AKI Audit -					Username Optio
ES Extracted Identifiers Discharge Dev	elopment of AKI	Timely Completion of AKI Revie	w Timely Completion of AKI Int	eventions Life	e threatening complications
ephrology Involvement ITU Involvement	TTO				
i ay and a short and a short and a short and a short a					
ischarge date from the hospital					
					
enal function back to baseline*					
Not Completed	~				
ntered maintenance dialysis*		Did the patient die?*			
Not Completed	~	Not Completed	~		
		In-hospital death			
e-admitted within 90 days*					
Not Completed	~				
ength of stay					
0					
utofilled from admission date and discharged date or dear	th date				
Save progress					
phwork Home AKI Audit 👻					Username Optic
odate Record					
	nent of AVI	y Completion of AKI Review Time	ely Completion of AKI Inteventions	ife threaten is a	mplications Nonbrology Involvement
	Interit OF ANI LIMELY	y completion of AKI Review Time	ay completion of AKI inteventions 1	ife threatening cor	mplications Nephrology Involvement
S Extracted Identifiers Discharge Developm					
S Extracted Identifiers Discharge Developm					
S Extracted Identifiers Discharge Developm J Involvement TTO		Location*		Date of AKI 1st	warning test result
S Extracted Identifiers Discharge Developm J Involvement TTO	=	Location*		Date of AKI 1st	warning test result
S Extracted Identifiers Discharge Developm J Involvement TTO ate of clinical development of AKI				~	warning test result
S Extracted Identifiers Discharge Developm J Involvement TTO ate of clinical development of AKI s date should be less than 7 days before admission and dischar				~	
S Extracted Identifiers Discharge Developm J Involvement TTO ate of clinical development of AKI s date should be less than 7 days before admission and dischar		Not Completed		This date should be	
S Extracted Identifiers Discharge Developm J Involvement TTO ate of clinical development of AKI date should be less than 7 days before admission and dischar eatinine peak (umol/L)		Not Completed		This date should be	
S Extracted Identifiers Discharge Developm J Involvement TTO ate of clinical development of AKI is date should be less than 7 days before admission and dischar eattnine peak (umol/L) bected range is 30 to 2000		Date		This date should be	
S Extracted Identifiers Discharge Developm J Involvement TTO ate of clinical development of AKI is date should be less than 7 days before admission and dischar eattnine peak (umol/L) bected range is 30 to 2000		Not Completed Date Date of measurement		This date should be	
S Extracted Identifiers Discharge Developm J Involvement TTO the of clinical development of AKI a date should be less than 7 days before admission and dischar eatinine peak (umol/L) peeted range is 30 to 2000 seline creatinine	ge date	Not Completed Date Date of measurement		This date should be	
S Extracted Identifiers Discharge Developm J Involvement TTO ate of clinical development of AKI is date should be less than 7 days before admission and dischar eatinine peak (umol/L) pected range is 30 to 2000 seeline creatinine west in last 7 days. If no bloods in last 7 days use average for last reg is 30 to 2000	ge date	Not Completed Date Date of measurement. Date		This date should be	
S Extracted Identifiers Discharge Developm J Involvement TTO ate of clinical development of AKI is date should be less than 7 days before admission and dischar eatinine peak (umol/L) pected range is 30 to 2000 isseline creatinine west in last 7 days. If no bloods in last 7 days use average for lat ge is 30 to 2000 as the renal function re-checked within 30 days?*	ge date at 12 months. Expected	Not Completed Date Date Date		This date should be	
S Extracted Identifiers Discharge Developm J Involvement TTO ate of clinical development of AKI is date should be less than 7 days before admission and dischar reatinine peak (umol/L) pected range is 30 to 2000 useline creatinine west in last 7 days. If no bloods in last 7 days use average for las rage is 30 to 2000 fast he renal function re-checked within 30 days?* Not Completed	ge date st 12 months. Expected	Not Completed Date Date of measurement Date deally, this would be in the last 7 days		This date should be	
SE Strated Identifiers Discharge Development TTO ate of clinical development of AKI is date should be less than 7 days before admission and dischar reatinine peak (umol/L) pected range is 30 to 2000 aseline creatinine wext in last 7 days. If no bloods in last 7 days use average for las nge is 30 to 2000 as the renal function re-checked within 30 days?* Not Completed eatinine within day 30 after discharge. Date required if answer is	ge date st 12 months. Expected	Not Completed Date Date of measurement Date deally, this would be in the last 7 days		This date should be	
ES Extracted Identifiers Discharge Development TTO ate of clinical development of AKI is date should be less than 7 days before admission and dischar reatinine peak (umol/L) pected range is 30 to 2000 aseline creatinine wext in last 7 days. If no bloods in last 7 days use average for las nge is 30 to 2000 as the renal function re-checked within 30 days?* Not Completed eatinine within day 30 after discharge. Date required if answer is KI cause	ge date st 12 months. Expected	Not Completed Date Date Date Date Date Date Date Date Consultant review in 6 hours*		This date should be	
S Extracted Identifiers Discharge Developm J Involvement TTO ate of clinical development of AKI is date should be less than 7 days before admission and dischar reatinine peak (umol/L) pected range is 30 to 2000 aseline creatinine west in last 7 days. If no bloods in last 7 days use average for las rage is 30 to 2000 as the renal function re-checked within 30 days?* Not Completed eatinine within day 30 after discharge. Date required if answer is	ge date st 12 months. Expected	Not Completed Date Date Date Date	post development of ARI within 6 Hours? (review-	This date should be	

Username Options -

Username Options

Update Record

HES Extracted Identifiers Discharge Deve	elopment of AKI Timely Completion of AKI Review	Timely Completion of AKI Inteventions	ife threatening complications	Nephrology Involvement	ITU Involvement
тто					
Antibiotics indicated*	Requested*		Completed*		
Not Completed	✓ Not Completed		✓ Not Completed		~
Within 1 hour	Within 1 hour		Within 1 hour		
IV fluids indicated*	Requested*		Completed*		
Not Completed	✓ Not Completed		✓ Not Completed		~
Diuretics indicated*	Requested*		Completed*		
Not Completed	✓ Not Completed		✓ Not Completed		~
Bladder catherization indicated*	Requested*		Completed*		
Not Completed	✓ Not Completed		✓ Not Completed		~
Nephrostomy/stent indicated*	Requested*		Completed*		
Not Completed	✓ Not Completed		✓ Not Completed		~
Save progress					

Nephwork Home AKI Audit 👻

Update Record

HES Extracted Identifiers Discharge Devel	opment of AKI Timely Completion of AKI Review	Timely Completion of AKI Inteventions Life	e threatening complications	Nephrology Involvement	ITU Involvement
то					
Antibiotics indicated*	Requested*		Completed*		
Not Completed	✓ Not Completed	`	✓ Not Completed		
Within 1 hour	Within 1 hour		Within 1 hour		
IV fluids indicated*	Requested*		Completed*		
Not Completed	✓ Not Completed	`	✓ Not Completed		
Diuretics indicated*	Requested*		Completed*		
Not Completed	✓ Not Completed	•	✓ Not Completed		
3ladder catherization indicated*	Requested*		Completed*		
Not Completed	✓ Not Completed	`	✓ Not Completed		
Nephrostomy/stent indicated*	Requested*		Completed*		
Not Completed	 Not Completed 		 Not Completed 		

Nephwork Home AKI Audit *

Update Record

HES Extracted Identifiers	Discharge	Development of AKI	Timely Completion of AKI Review	Timely Completion of AKI Inteventions	Life threatening complications	Nephrology Involvement	ITU Involvement
TTO							

TTO Hyperkalaemia*

Hyperkalaemia^	
Not Completed	~
Pulmonaryodema*	
Not Completed	~
Acidosis*	
Not Completed	~
Uraemia*	
Not Completed	~
Was nephrology referral indicated?*	
Not Completed	~
Did the referral happen?*	
Not Completed	~
Save progress « Previous Next »	

Nephwork	Home	
----------	------	--

Update Record

HES Extracted Identifiers	Discharge	Development of AKI	Timely Completion of AKI Review	Timely Completion of AKI Inteventions	Life threatening complications	Nephrology Involvement	ITU Involvement
TTO							
One off advice*							
Not Completed			~				
Ongoing review*							
Not Completed			~				
Take-over including RRT*							
Not Completed			~				
ITU took over from nephro	ology*						
Not Completed			~				
Transferred to secondary re	enal care*						
Not Completed			~				
Save progress « Previ	ious Next »						

phwork Home AKI Audit 👻					Username Options
pdate Record					
ES Extracted Identifiers Discharge Development of Al	KI Timely Completion of AKI Review	Timely Completion of AKI Inteventions	Life threatening complications	Nephrology Involvement	ITU Involvement
Ю					
dvice from intensivist*					
Not Completed	~				
ake-over supportive management*					
Not Completed	~				
ake-over RRT*					
Not Completed	~				
lot a candidate for ITU*					
Not Completed	~				
ease respond yes if the patient was not a candidate					
/as there a delay if deemed for RRT?*					
Not Completed	~				
24hrs from decision					

ephwork Home AKI Audit 👻						Username Options
Jpdate Record						
HES Extracted Identifiers Discharge Development of AKI	Timely Completion of AKI Review	Timely Completion of AKI Inteventions	Life tł	nreatening complications	Nephrology Involvement	ITU Involvement
TTO						
AKI mentioned on TTO*	Followup of unresolved re	enal function documented on TTO*		GP instructions re medicine	e and bloods on TTO*	
Not Completed	✓ Not Completed		~	Not Completed		~
90 day renal followup if CKD4*	30 day renal followup if C	KD5 or Dialysis*				
Not Completed	✓ Not Completed		~			